Update on the pathogenesis of Scleroderma: focus on circulating progenitor cells

Area of Science:

• Immunology
• Cell Biology
• Rheumatology

Background:

• Systemic sclerosis (SSc) involves fibrosis, potentially stemming from endothelial injury and an unknown trigger.
• Circulating progenitor cells (CPCs) are implicated in SSc pathogenesis due to their multipotent differentiation capabilities.
• CPCs can exhibit macrophage, fibroblast, and endothelial cell characteristics, migrating to injury sites.

Purpose of the Study:

• To identify and characterize distinct subsets of circulating progenitor cells (CPCs) in systemic sclerosis (SSc).
• To investigate the role of these CPC subsets in the fibrotic and vascular manifestations of SSc.
• To explore the potential of CPC differentiation patterns for patient classification and targeted therapies.

Main Methods:

• Identification of six CPC subsets based on specific cell surface markers (e.g., CD14, CD34, CD45, VEGFR2, Col I).
• Analysis of CPC marker expression and differentiation stages in SSc patients.
• Correlation of CPC levels and types with clinical phenotypes, including fibrosis and interstitial lung disease.

Main Results:

• Six CPC subsets were identified, originating from CD14+ monocyte precursors, with varying differentiation degrees.
• Elevated levels of activated CD14+ monocytes and early endothelial progenitor cells (EPCs) were observed in SSc patients.
• Increased numbers of CD14+, CD34+, Col I+ cells were found in the lungs of SSc patients with interstitial lung disease.
• CPC marker expression (e.g., CXCR4, CD34, CD45) varied with differentiation, suggesting a continuous developmental process.

Conclusions:

• Circulating progenitor cell subsets play a significant role in the pathophysiology of systemic sclerosis.
• The differentiation state of CPCs correlates with disease phenotype, including fibrosis and vascular involvement.
• Further understanding of CPC subtypes can facilitate personalized treatment strategies for SSc patients.